DermTech, Inc.

OTCPK:DMTK.Q Aktierapport

Börsvärde: US$35.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DermTech Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

DermTech har ökat intäkterna med en genomsnittlig årlig takt på 23.9%, medan Biotechs -branschen såg intäkterna växande på 33.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 9.7% per år.

Viktig information

23.94%

Tillväxttakt i vinsten

31.76%

Tillväxttakt för EPS

Biotechs Tillväxt i branschen17.04%
Intäkternas tillväxttakt9.71%
Avkastning på eget kapital-224.10%
Nettomarginal-572.19%
Senaste uppdateringen av resultatet31 Mar 2024

Senaste uppdateringar av tidigare prestationer

Recent updates

Analysartikel • May 21

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 44% in the last...
Analysartikel • Mar 02

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 28% in the last...
Analysartikel • Dec 28

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

You may think that with a price-to-sales (or "P/S") ratio of 4.5x DermTech, Inc. ( NASDAQ:DMTK ) is definitely a stock...
Analysartikel • Sep 18

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Jun 14

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • May 10

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

One thing we could say about the analysts on DermTech, Inc. ( NASDAQ:DMTK ) - they aren't optimistic, having just made...
Analysartikel • May 06

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 37% in the last...
Analysartikel • Jan 16

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Nov 08

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

The latest analyst coverage could presage a bad day for DermTech, Inc. ( NASDAQ:DMTK ), with the analysts making...
Analysartikel • Oct 11

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 11

DermTech grants stock options

DermTech (NASDAQ:DMTK) granted one new, non-executive employee non-qualified stock options to buy ~38.78K common shares. The stock options, which have an exercise price of $4 per share, were granted under Inducement Equity Incentive Plan, the company said in an Oct. 10 press release.
Seeking Alpha • Sep 01

Diving Into DermTech

Summary Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning. A full investment analysis of DermTech follows in the paragraphs below. Come friends, it's not too late to seek a newer world.”― Alfred Lord Tennyson Today, we put the spotlight on a small diagnostic firm called DermTech, Inc. (DMTK). This company has what it is a potential "best of breed" and non-invasive way to test for melanoma. Its core product is seeing some sales traction and the company currently has a lot of cash on the balance sheet. However, cash burn is a major concern around DermTech. An analysis follows below. Seeking Alpha Company Overview: DermTech, Inc. is a molecular testing concern based out of La Jolla, California. The company develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the U.S. The shares currently trade around $5.50 a share and sport an approximate market capitalization of $170 million. November 2021 Company Presentation The company's non-invasive tests to diagnose skin conditions that are more effective than traditional biopsy-based diagnostic tests. The company's main test right now is called the DermTech Smart Sticker. This replaces a scalpel to remove the skin cells off the surface of a mole. The DermTech Smart Sticker provides an accurate, non-invasive test to detect melanoma. November Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. DermTech had a GAAP loss of 99 cents a share, slightly better than the consensus. Revenues rose nearly 36% on a year-over-year. However, revenues were only $4.23 million, and that was somewhat under expectations. The company's net loss for the quarter widened to $29.6 million compared with a loss of $17.1 million in 2Q2021. Assay revenue increased by over 40% to $4.15 million while contract revenue declined some 60% to just to $86,000. Billable sample volume grew 56% to 18,320 compared to the same period a year ago. The company also saw a 67% increase in unique ordering clinicians to approximately 2,390. Thanks to continued acceptance, DermTech Smart Sticker is now available to approximately 91 million covered lives. This breaks down as nearly 68 million for Medicare and Medicare Advantage and 23 million for commercial payers, which largely comes today from the Blue Shields of California, Illinois and Texas. The stock got hit when management took down their full year assay revenue estimate to $16 million to $19 million from $22 million to $26 million previously. The company has streamlined the laboratory processes, which reduced the per unit cost of the DermTech Smart Sticker by 28% sequentially to $177 per, but the product is also seeing a lower average selling price, or ASP, which is a key reason for the downward sales guidance revision. ASP was under pressure due to Medicare billing code edits, which are expected to be improved in the coming quarters. The company is pushing the launch of their direct-to-consumer offering "Luminate" that assesses skin cancer risk to the first half of 2023 to conserve costs. Analyst Commentary & Balance Sheet: Since second quarter results came out, four analyst firms including BTIG and Oppenheimer have reiterated Buy ratings. However, all four analyst firms significantly cut their price targets on DermTech. Price targets now proffered range from $14 to $24 a share. Prior to price target revisions, price targets from these four analyst firms was in the $19 to $48 range. Approximately one out of eight shares are currently held short. Numerous insiders have been frequent, but mostly small, sellers of the stock in 2022. They have sold approximately $500,000 worth of equity in aggregate so far this year. The last insider purchases of DMTK were in February of 2020. The company ended the second quarter of this year with just north of $175 million worth of cash and marketable securities on its balance sheet. Leadership believes this is sufficient capital to fund its current operating plan through the first quarter of 2024 Verdict: The current analyst consensus has the company losing nearly four bucks a share in FY2022 even as revenues advance over 50% to some $18 million. Next year, revenue growth is expected to accelerate with the company doing some $30 in sales in FY2023. However, losses are expected to only come down around 10%.
Analysartikel • Aug 10

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

One of the biggest stories of last week was how DermTech, Inc. ( NASDAQ:DMTK ) shares plunged 33% in the week since its...
Seeking Alpha • Jun 13

DermTech: Approaching An All Or Nothing Moment

DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company’s salesforce. Although the company’s solutions have enormous potential and could drive the stock price significantly higher if successfully commercialized, recent management guidance for the next 12 months was soft. The future outcome for DMTK may be binary - either massive success driven by mass product adoption or a slow fade to oblivion based on failed commercialization.
Analysartikel • Jun 04

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 31

DermTech - Taking A Second Look At The Growth Thesis

DMTK’s SmartSticker solution is proprietary and has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches, but the company must further commercialize this offering. DMTK has made significant sales, marketing and infrastructure investments over the past 6 months, which should drive 2022 to be a record financial year for the company. Investors should approach this opportunity with caution while collecting more data on DMTK’s ability to grow sales. The longer-term opportunity remains if DMTK can execute on its core growth strategies.
Seeking Alpha • Dec 23

DermTech: Adoption Headwinds And Earnings Misses

DMTK has a skin cancer diagnostics test in the market. The company has repeatedly missed earnings, and this time, they also lowered guidance. This sort of steady depletion of shareholder value does not look good for future investments.

Fördelning av intäkter och kostnader

Hur DermTech tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

OTCPK:DMTK.Q Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
31 Mar 2416-907414
31 Dec 2315-1018315
30 Sep 2314-1109017
30 Jun 2314-1209719
31 Mar 2314-1189822
31 Dec 2215-1179524
30 Sep 2215-1159225
30 Jun 2214-1068424
31 Mar 2213-937520
31 Dec 2112-786216
30 Sep 2111-635012
30 Jun 219-52419
31 Mar 217-45357
31 Dec 206-36305
30 Sep 205-31274
30 Jun 205-27243
31 Mar 204-21193
31 Dec 193-20152
30 Sep 192-18122
30 Jun 192-1482
31 Mar 193-1372
31 Dec 182-1062
31 Dec 172-862

Kvalitetsintäkter: DMTK.Q är för närvarande olönsam.

Växande vinstmarginal: DMTK.Q är för närvarande olönsam.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: Otillräcklig data för att avgöra om DMTK.Q s resultattillväxt på årsbasis var positiv under de senaste 5 åren.

Accelererande tillväxt: Det går inte att jämföra DMTK.Q s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt

Resultat vs industri: DMTK.Q är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 43% ).

Avkastning på eget kapital

Hög ROE: DMTK.Q har en negativ avkastning på eget kapital ( -224.1% ), eftersom det för närvarande är olönsamt.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/07/23 04:51
Aktiekurs vid dagens slut2025/07/23 00:00
Intäkter2024/03/31
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

DermTech, Inc. bevakas av 10 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Sally YanchusBrookline Capital Markets
Mark MassaroBTIG
Alexander NowakCraig-Hallum Capital Group LLC